Novogen

Novogene

Novogene delivers unsurpassed data quality to support our customer’s research goals. Novogene is a world-leader in NGS services, with thousands of employees and multiple locations across the globe. Novogene has strong scientific expertise and experience with 37 NGS-related patents, as well as over 670 research papers with total impact factor at more than 4930, including publications in first tiers journals such as Cell, Nature and Science.

As the largest NGS service provider headquartered in Beijing with branches in Hong Kong China, US, UK, Singapore, Netherlands, Japan and Thailand, Novogene was founded in 2011 and has been growing rapidly over the past few years. Novogene has genomic sequencing labs in the US (at The University of California at Davis campus), China, Singapore, and the UK (Cambridge).

Devices:

• HiSeq X
• HiSeq 2000/2500/4000
• NextSeq 500
• MiSeq
• S5XL
• Sequel
• NovaSeq

Human Animal and Plants Whole Genome Sequencing
Human Whole Exome Sequencing
Eukaryotic RNA Sequencing
Prokaryotic RNA Sequencing
Metatranscriptome Sequencing
Eukaryotic Long non-Coding RNA Sequencing
Small RNA Sequencing
Whole Genome Bisulfite Sequencing
Bacterial Genome de novo Sequencing
Fungal Genome de novo Sequencing

     The Result of 550 gene panel for cancer includes:
Testing Results:
Relevant Targeted Drug
Relevant chemotherapeutic Drug
Test Result interpretation:
Gene Mutations and Relevant Targeted Drugs
Chemotherapy Related Genomic Alterations Detected
Targeted Therapy Related Common Genomic Alterations Detected
Genomic Alterations Detected is Signaling Pathways List of Genes Analyzed

کلیه حقوق این سایت نزد گروه درمان نگار آیندگان محفوظ است.